Start Here: a Drug Is Just a Molecule That Binds Something
Strip away every brand name and the whole of pharmacology reduces to one idea: a drug is a small molecule that binds to a larger molecule in or on a cell, and changes what that larger molecule does. It does not invent a new function. It nudges, blocks or amplifies a process the body already runs. Oxytocin does not "make the uterus contract" by command; it occupies a receptor the myometrium already built, and that receptor's own machinery raises calcium and tightens the contractile apparatus. Penicillin does not "kill bacteria" by force; it jams an enzyme the bacterium needs to finish its wall.
So the first principle to anchor on is this:
Drugs work by binding a target. The target is a molecule the body (or the microbe) already uses. The cell's existing machinery does the rest.
Everything else in this chapter is just naming the targets and tracing what happens after binding. If you hold onto that single sentence, an unfamiliar drug in an exam stem stops being a memory test and becomes a reasoning problem.
The Chain You Will Use Everywhere
Once a drug binds, the consequence flows along a predictable chain. We will return to this chain in every section, so learn it now:
drug binds target → an intracellular signal changes → the tissue does something different → that helps or harms the patient
| Link | The question to ask | Worked answer (oxytocin) |
|---|---|---|
| Target | What molecule does the drug bind? | The myometrial oxytocin receptor |
| Signal | What changes inside the cell? | Calcium rises; the contractile machinery is primed |
| Tissue effect | What does the organ now do? | Coordinated myometrial contraction |
| Clinical effect | Why does this help? | Labour augmentation; the contracted uterus compresses bleeding vessels after delivery |
| Predictable toxicity | What if the same pathway is pushed too far? | Tachysystole, reduced placental perfusion, fetal compromise |
The last row matters as much as the first. Toxicity is usually the wanted effect taken too far, or the same target hit in the wrong tissue. That is why "side effects" are rarely random — they are the mechanism showing its other face.
The Handful of Targets a Drug Can Bind
There are not hundreds of kinds of drug action. There are only a few molecular targets, and almost every medicine you will ever prescribe in O&G acts through one of them. Learn the list, and a new drug just slots into a category you already understand.
| Target | The cellular principle | O&G example |
|---|---|---|
| Receptors | The drug mimics, blocks or tunes a signal the body already sends | Oxytocin, prostaglandins, progestins, beta-agonists |
| Ion channels | The drug changes ion flow, so excitability or contraction changes | Local anaesthetics, calcium-channel blockers, magnesium effects |
| Enzymes | The drug blocks (or rarely boosts) a biochemical reaction | NSAIDs inhibit cyclo-oxygenase; aromatase inhibitors cut oestrogen synthesis |
| Transporters | The drug changes movement across a membrane | Renal tubular secretion, neurotransmitter re-uptake, placental transfer |
| DNA / RNA / mitosis | The drug interferes with replication or cell division | Cytotoxic chemotherapy, methotrexate, some antivirals |
| Microbial structures | The drug hits a structure the host does not have | Cell-wall, ribosome, DNA gyrase or folate-pathway antimicrobials |
| Immune mediators | The drug suppresses or redirects inflammation | Corticosteroids, biologics, antihistamines |
The same target can heal or harm depending on tissue, timing and dose. Prostaglandins ripen a cervix and contract a uterus where you want them, but cause unwanted hyperstimulation when overdone. NSAIDs relieve dysmenorrhoea by lowering prostaglandins, yet the same prostaglandin suppression late in pregnancy threatens fetal renal blood flow and the patency of the ductus arteriosus. Corticosteroids mature fetal lungs and quieten autoimmune disease, but the same broad transcriptional effect raises maternal glucose and infection risk.
Notice that several of these targets — receptors, enzymes, ion channels — are exactly the pieces of the cell's own signal-transduction machinery. Before we go target by target, we need to understand that machinery, because it is the "signal" link of the chain. Without it, "binds receptor" and "tissue contracts" are two facts with nothing in between.
The Bridge: Second Messengers Connect Binding to Behaviour
Here is the part that turns memorisation into understanding. When a water-soluble drug or hormone binds a receptor on the outside of the cell, the molecule itself never gets in. The message has to be carried across the membrane and amplified inside. The cell does this with a small set of second messengers — internal signalling molecules that the surface receptor switches on. There are only a few worth knowing, and they explain most drug effects in obstetrics.
| Second messenger | How it is made | What it does inside the cell |
|---|---|---|
| Cyclic AMP (cAMP) | Adenylate cyclase, switched on by a stimulatory G-protein (Gs) | Activates protein kinase A, which phosphorylates target proteins; in smooth muscle this favours relaxation |
| Calcium (Ca²⁺) | Channels open in the membrane or endoplasmic reticulum | Binds calmodulin; the calcium–calmodulin complex activates myosin light-chain kinase, driving smooth-muscle contraction |
| IP₃ and diacylglycerol (DAG) | A Gq-linked receptor activates phospholipase C, which splits a membrane lipid (PIP₂) into IP₃ and DAG | IP₃ releases calcium from internal stores; DAG activates protein kinase C |
| Cyclic GMP (cGMP) | Guanylate cyclase, switched on by nitric oxide or by natriuretic-peptide receptors | Drives vascular and myometrial smooth-muscle relaxation |
Two of these messengers are worth pausing on because they decide whether smooth muscle tightens or loosens — the central question in obstetric pharmacology.
Calcium is the contraction signal. A resting cell keeps free calcium astonishingly low (around 10⁻⁷ mol/L) against a much higher concentration outside (around 10⁻³ mol/L), using ATP-driven pumps. When a signal lets calcium flood in, calcium binds calmodulin, calmodulin activates myosin light-chain kinase, and the actin–myosin apparatus contracts. Anything that raises myometrial calcium tends to contract the uterus; anything that lowers it relaxes the uterus. This single fact explains oxytocin (raises calcium → contracts), calcium-channel blockers (block calcium entry → relax), and magnesium (competes with calcium → relaxes).
cAMP is, broadly, the relaxation signal in smooth muscle. A beta-2 agonist binds a Gs-linked receptor, adenylate cyclase makes cAMP, cAMP activates protein kinase A, and protein kinase A inhibits myosin light-chain kinase and lowers free calcium — so the muscle relaxes. That is the entire mechanism of beta-agonist tocolysis in one sentence, and it is also why the same drug relaxes bronchi in asthma.
Nitric oxide works through cGMP. Nitric oxide is a gas, small enough to slip straight into the cell, where it activates guanylate cyclase to make cGMP and relaxes vascular smooth muscle. It is produced from L-arginine by nitric-oxide synthase, has a half-life of only a few seconds, and is a major reason blood pressure falls in normal pregnancy. The same chemistry explains why nitrate drugs (which break down to nitric oxide) relax blood vessels.
Now the chain has a middle. "Binds receptor → contracts" becomes "binds receptor → Gq → phospholipase C → IP₃ → calcium release → myosin light-chain kinase → contraction." You can reconstruct that for almost any signalling drug if you know which messenger its receptor uses.
Receptor-Mediated Drug Action
Cells respond to a drug only if they express its target receptor and possess the downstream machinery. This is why the same hormone behaves differently in uterus, breast, liver, bone and brain — the receptor and its second-messenger wiring differ by tissue.
| Receptor class | How the signal crosses the membrane | O&G application |
|---|---|---|
| G-protein coupled receptor (GPCR) | A seven-pass membrane protein that activates a G-protein → cAMP, IP₃/DAG or calcium | Oxytocin, prostaglandins, beta-agonists, adrenergic and muscarinic drugs |
| Ligand-gated ion channel | Binding opens the channel directly; ions flow at once | Fast neurotransmission; neuromuscular and anaesthetic principles |
| Voltage-gated channel | Opens with a change in membrane voltage | Local-anaesthetic sodium-channel block; calcium-channel blockers |
| Enzyme-linked receptor | A single-pass receptor whose inner end is (or recruits) an enzyme, usually a kinase | Insulin, growth-factor and VEGF signalling |
| Nuclear (intracellular) receptor | The lipid-soluble drug crosses the membrane and binds a receptor that acts as a transcription factor | Oestrogen, progesterone, glucocorticoid, thyroid hormone |
The GPCR family is the largest in the body (over 800 members) and the workhorse of obstetric pharmacology. The mechanism is worth holding precisely: a ligand binds, the receptor changes shape, it activates a trimeric G-protein (subunits α, β, γ), the α-subunit swaps GDP for GTP and dissociates, and that active α-subunit switches an enzyme like adenylate cyclase on or off. A stimulatory G-protein (Gs) raises cAMP; an inhibitory G-protein (Gi) lowers it; a Gq protein drives the IP₃/calcium arm. The same neurotransmitter can therefore raise cAMP through one receptor subtype and lower it through another — adrenaline does exactly this at different adrenoceptors.